EUVIMEDEUVIMED entdecken
Crossref

SARS-CoV-2 infection produces an IL-33-dependent chronic eosinophilic pneumonia and muco-inflammatory airways disease in mice

Robert S. Hagan, Lauren K. Heine, Minako Saito, Raymond John Pickles, James J. Pestka, Jack R. Harkema, Stephen A. Schworer, E F Burns, Richard C. Boucher, Jason R. Rock, Kenichi Okuda, Lisa C. Morton und 8 weitere

Carolina Digital Repository (University of North Carolina at Chapel Hill) · 16.07.2026

DOI: 10.17615/qxcw-3z04 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Carolina Digital Repository (University of North Carolina at Chapel Hill), erschienen am 16.07.2026. Verfasst von Robert S. Hagan und 19 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Post-acute sequelae of SARS-CoV-2 (PASC) occurs in subsets of individuals, including those with pre-existing lung disease. To investigate PASC pathogenesis and therapeutics in a chronic bronchitis mouse model (Scnn1b-Tg), Scnn1b-Tg and WT mice were inoculated with a mouse adapted SARS-CoV-2 virus (SARS-CoV-2MA10) and followed for 60 days. Viral titer, histology, immunohistochemistry (IHC), single-cell RNA sequencing, RNA in situ hybridization, and spatial transcriptomic profiling characterized disease pathologies. Scnn1b-Tg mice inoculated with SARS-CoV-2MA10 exhibited lower viral titers and less weight loss than WT mice. Airway epithelia of Scnn1b-Tg mice were less infected than epithelia of WT mice, reflecting increased airway mucus and enhanced epithelial antiviral activities in Scnn1b-Tg mice. However, Scnn1b-Tg mice subsequently exhibited heterogeneous airway and parenchymal disease with elevated Il33 expression characteristic of human eosinophilic pneumonia. Cohorts of infected mice were administered a monoclonal antibody targeting the IL-33 receptor (ST2) or enteral prednisone. Administration of an anti-ST2 monoclonal antibody mitigated development of eosinophilic pneumonia while enteral prednisone suppressed IL33 expression and disease. The eosinophilic pneumonia in Scnn1b-Tg mice after SARS-CoV-2MA10 infection mimics reports of eosinophilic pneumonia in humans post-SARS-CoV-2, suggesting targeting of IL-33 may be beneficial in treating post-viral eosinophilic pneumonia in humans.

Schlagwörter

SARS-CoV-2post-COVID-19 sequelaeeosinophilic pneumoniaIL-33ST2 receptorchronic bronchitisairway mucus hypersecretionprednisonemouse model

Zitieren

APA

Hagan, R. S., Heine, L. K., Saito, M., Pickles, R. J., Pestka, J. J., Harkema, J. R., Schworer, S. A., Burns, E. F., Boucher, R. C., Rock, J. R., Okuda, K., Morton, L. C., Schäfer, A., Gilmore, R. C., O’Neal, W. K., Baric, R. S., Livraghi-Butrico, A., Hawkins, P., Dang, H., & Leist, S. R. (2026). SARS-CoV-2 infection produces an IL-33-dependent chronic eosinophilic pneumonia and muco-inflammatory airways disease in mice. Carolina Digital Repository (University of North Carolina at Chapel Hill). https://doi.org/10.17615/qxcw-3z04

Vancouver

Hagan RS, Heine LK, Saito M, Pickles RJ, Pestka JJ, Harkema JR, et al. SARS-CoV-2 infection produces an IL-33-dependent chronic eosinophilic pneumonia and muco-inflammatory airways disease in mice. Carolina Digital Repository (University of North Carolina at Chapel Hill). 2026. doi:10.17615/qxcw-3z04

BibTeX
@article{Hagan2026,
  author = {Hagan, Robert S. and Heine, Lauren K. and Saito, Minako and Pickles, Raymond John and Pestka, James J. and Harkema, Jack R. and Schworer, Stephen A. and Burns, E F and Boucher, Richard C. and Rock, Jason R. and Okuda, Kenichi and Morton, Lisa C. and Schäfer, A and Gilmore, Rodney C. and O’Neal, Wanda K. and Baric, Ralph Steven and Livraghi-Butrico, Alessandra and Hawkins, Padraig and Dang, H and Leist, Sarah R.},
  title = {SARS-CoV-2 infection produces an IL-33-dependent chronic eosinophilic pneumonia and muco-inflammatory airways disease in mice},
  journal = {Carolina Digital Repository (University of North Carolina at Chapel Hill)},
  year = {2026},
  doi = {10.17615/qxcw-3z04}
}
Kostenlos starten →